1 0
Cart
    Inquiry
    Popular Searches: Recombinant Antibody MHC Tetramer T cell Receptor Scaffold Protein
    + Filter
    Loading...
    Custom Services order now ship next day

    GD2 & FcγRIII

    Loading...

    Anti-GD2 & FcγRIII Products

    View More Products

    Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

    More Infomation

    Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

    For Research Use Only. Not For Clinical Use.


    Background

    This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
    GD2 is a disialic ganglioside expressed in tumors of neuroectodermal origin (including human neuroblastoma and melanoma), and its expression in normal tissues (mainly human cerebellum and peripheral nerves) is highly restricted.
    The relative tumor-specific expression of GD2 makes it a suitable target for immunotherapy using monoclonal antibodies or artificial T cell receptors. An example of such an antibody is hu14.18K322A, a monoclonal antibody. The anti-GD2 antibody is currently in phase II clinical trials for the treatment of previously untreated high-risk neuroblastoma and combined chemotherapy prior to stem cell transplantation and radiation therapy. A previous phase I clinical trial designed to reduce toxicity in patients with refractory or recurrent neuroblastoma found a safe dose and determined that common toxicity, especially pain, can be well controlled.
    GD2 & FcγRIII
    Go to compare

    Go to compare